icon-folder.gif   Conference Reports for NATAP  
 
  EASL 46th Annual Meeting
March 30th - April 3rd 2011
Berlin, Germany
Back grey_arrow_rt.gif
 
 
 
Once daily alisporivir (DEB025) plus Peg-IFN-alfa-2A/ ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients - The ESSENTIAL study
 
 
  Reported by Jules Levin
EASL March 31 2011 Berlin Germany
 
R Flisiak1, JM Pawlotsky2, R Crabbe3, PI Calistru4,
W Kryczka5, D Haussinger6, G Mazella7, M Romero8,
D Purcea3, G Vuagniaux3, W Bao9, C Avila9 and S Zeuzem10
 
1Medical University of Bialystok, Bialystok, Poland; 2Hopital Henri Mondor, Creteil, France; 3Debiopharm, Lausanne, Switzerland; 4Centrul de Diagnostic si Tratament Dr. Viktor Babes, Bucharest, Romania; 5Provincial Hospital, Kielce, Poland; 6Universitatsklinikum, Düsseldorf, Germany; 7University of Bologna, Bologna, Italy; 8Hospital Universitario Nuestra Seņora de Valme, Sevilla, Spain; 9Novartis Pharma AG, Basel, Switzerland; 10J.W. Goethe University Hospital, Frankfurt, Germany

croi1.gif

croi2.gif

croi3.gif

croi4.gif

croi5.gif

croi6.gif

croi7.gif

croi8.gif

croi9.gif

croi10.gif

croi11.gif

croi12.gif